TOTAL	TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Applic Filing	ati n Number Date	09/832,510 April 10, 2001
				First N	lamed Invent r	Rose, Larry ILIN 1 9 200
				Group	Art Unit	1642 JUN 1 2 208
				Examiner Name		Huff, Sheela Jitenora CENTER 1600
[Total Number of Pages in This	3	Attorne	ey Docket Number	02307O-087910US	
	ENCLOSURES (check all that apply)					
	Fee Transmittal Form		Assignment Papers (for an Application)			After Allowance Communication to Group
	Fee Attached		Drawing(s)			Appeal Communication to Board of Appeals and Interferences
	Amendment / Response		Licensing-related Papers		d Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
	After Final		Petition Routing Slip (PTO/SB/69) and Accompanying Petition			Proprietary Information
	Affidavits/declaration(s)		Petition to Convert to a Provisional Application			Status Letter
	Extension of Time Request		Power of Attorney, Revocation Change of Correspondence Address			Other Enclosure(s) (please identify below):
/	Express Abandonment Request		Terminal Disclaimer			Retum Postcard
<i>'</i>			Request for Refund			
	☐ Information Disclosure Statement☐ Certified Copy of Priority		l '			authorized to charge any additional fees to
	Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Communication under 37 CFR §§ 1.821-1.825 and Amendment mailed concurrently to Box Sequence, P.O. Box 2327, Arlington, VA 22202.			
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
	Firm Towns and Individual name	rnsend and Crew LLP Reg. No. 35,551				
	Signature			2/		
	Date 5/28/02					
	CERTIFICATE OF MAILING					
	I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 5/28/02					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1350235 v1

Flocks /# 7 6.24.02

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT

Assistant Commissioner for Patents

Washington, D.C. 20231

on Main 28, 200

TOWNSEND and TOWNSEND and CREW LLP

By: With Mewell

RECEIVED

JUN 1 2 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ROSE et al.

Application No.: 09/832,510

Filed: April 10, 2001

For: ANTIGENIC EPITOPES WITH LYM-1 REACTIVITY AND USES

THEREOF

Examiner:

JUN 0 6 2002

Huff, Sheela Jitendra

Art Unit:

1642

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants respond herein to the Restriction Requirement mailed April 26, 2002 (the "Requirement"). No fees are believed to be due in connection with this Response; if, however, any fees are in fact due, the Commissioner is authorized to deduct them from Deposit Account 20-1430.

Applicants hereby elect Group I, claims 7-18, with traverse.

Applicants traverse the restriction. The Requirement states that two inventions are unrelated if it can be shown that they have different modes of operation, different functions, or different effects. The Requirement, however, does not show any of these things. It merely makes conclusory statements that the groups "are directed to different methods and involve the use of different reagents and have different steps." Applicants respectfully observe that these conclusory statements do not make a *prima facie* case that the methods have different modes of operation, different functions, or different effects. The fact that two methods may use different reagents, or have different steps, says nothing at all about the modes of operation, functions or effects of the methods. PCR, for example, would still seem to be conducted to amplify target nucleic

COPY OF PAPERS ORIGINALLY FILED ROSE et al.

Application No.: 09/832,510

Page 2

acids whether the reagent used is *Taq* polymerase or a polymerase first isolated from another thermophile. The fact that two methods have different steps is clearly to be expected, since otherwise the methods would be the same. It does not, by itself, show the methods have different operations, functions, or effects.

While the foregoing is sufficient to show that the requirement has not set forth a *prima facie* case, for the sake of good order, Applicants note that the Restriction is also deficient because it fails to show that there would be a serious burden on the Examiner to examine the claims together. MPEP § 803 requires examiners to examine claims together unless to do so would impose a serious burden on the examiner. The Requirement fails even to allege, let alone to show, that examining all the claims together in this application would impose a serious burden on the Examiner.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Laurence J. Hyman Reg. No. 35,551

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

LJH SF 1350166 v1